ClinicalTrials.gg
CompletedNCT03693963Updated Jan 28, 2021

The PRELUDE BTK Study

An interventional study of Serranator in Peripheral Arterial Disease and Critical Limb Ischemia, sponsored by Cagent Vascular LLC. Completed at 6 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-28.

Primary conditionChronic Limb-Threatening IschemiaRegistry: Peripheral Arterial DiseaseReclassifiedWhy we changed it
Registry
Peripheral Arterial Disease — the first condition term the registry derived for this study.
ClinicalTrials.gg
Chronic Limb-Threatening Ischemia
Why
  1. The study's listed conditions name Chronic Limb-Threatening Ischemia, a narrower term within Peripheral Arterial Disease.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Cagent Vascular LLC · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Apr 2020, 6 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Chronic Limb-Threatening Ischemia with a site in Germany — none open to participants now, 2 under way, none of them phase 3. Chronic Limb-Threatening Ischemia · Germany.

Enrollment
10th of 21
49 · median 49
Started
2019
with 2 others
No phase
10 of 32
none open now
Registered
23rd of 32
by date
Lead sponsor
2 of 32
Cagent Vascular LLC

Among the 32 studies in Chronic Limb-Threatening Ischemia with a site in Germany, this one is the 10th largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2019, is one of 10 with no phase, and was the 23rd registered.

Chronic Limb-Threatening Ischemia

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

Browse Chronic Limb-Threatening Ischemia studies →

Open to participants now

None of the 32 studies in Chronic Limb-Threatening Ischemia with a site in Germany is open now. The open studies under Chronic Limb-Threatening Ischemia, anywhere →

Who these studies take

Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 32 studies in Chronic Limb-Threatening Ischemia with a site in Germany as a file.
02

Study summary

The objective of the PRELUDE BTK study is to assess safety and efficacy of the Serranator® PTA Serration Balloon Catheter (study device) in subjects with atherosclerotic peripheral artery disease of the infrapopliteal arteries.

Read the detailed description

Single arm, prospective, multi-center feasibility study enrolling up to 48 subjects with atherosclerotic lesions in the infrapopliteal arteries and/or Critical Limb Ischemia (CLI). The study will capture acute angiographic data to compare the pre-Serranator® inflation vs post inflation effects and will include 6 month clinical follow up.

The study population will consist of subjects with claudication or CLI, with de novo stenoses or non-stented restenotic or total occlusion lesions in infrapopliteal arteries having lesion length up to and including 12 cm in length and reference vessel diameter of 2.5 mm to 3.5 mm inclusive.

03

Conditions studied

  • Peripheral Arterial Disease
  • Critical Limb Ischemia

Browse trials for

04

In context

Chronic Limb-Threatening Ischemia Reclassified

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

This study's enrollment of 49 is above the median of 41 across 240 interventional studies indexed under Chronic Limb-Threatening Ischemia.

Browse Chronic Limb-Threatening Ischemia studies →

Lead sponsor

Cagent Vascular LLC is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Compared within Chronic Limb-Threatening Ischemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Peripheral Arterial Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female of >18 years old.
  2. Women of child bearing potential must have a negative urine pregnancy test within 7 days of index procedure.
  3. Subject or subject's legal representative has been informed of the nature of the study, agrees to participate and comply with all follow-up visits and has signed the consent form.
  4. Subject is eligible for standard surgical repair in target limb if necessary.
  5. Subject has Rutherford Clinical Category 3, 4 or 5. Enrollment of Rutherford 3 will be limited to no more than 40% of total subjects.
  6. Estimated > 1 year.

Angiographic Inclusion Criteria:

  1. Target lesion(s) has stenosis >70% by visual assessment;
  2. De-novo, or non-stented re-stenotic lesions;
  3. Reference vessel diameter is between 2.5 mm and 3.5 mm, inclusive;
  4. Target lesions involve infra-popliteal tibial arteries above the tibio-talar joint;
  5. Up to two target lesion(s) may be treated. These target lesions may be located in a single or two infrapopliteal arteries;
  6. A target lesion may consist of one long or multiple serial lesions that are up to and including 12 cm in length that can be covered by a single balloon (longest balloon length for this study will be 12 cm);
  7. If more than one critical lesion is identified in two different vessels but only one lesion matches the inclusion criteria, that lesion should be treated as the target lesion and the other non-qualifying lesion in the other vessel may be treated with commercial devices in any manner the investigator decides except by atherectomy;
  8. If two critical lesions are identified in two vessels and both qualify for the study, the investigator may treat both lesions with balloons or may choose to identify one lesion as the target lesion and treat the second lesion with commercial devices except atherectomy;
  9. If two critical lesions are in one vessel and both lesions qualify for the study, both lesions should be treated with investigational balloons. Lesions that are within 3 cm of each other will be treated as a single lesion;
  10. Target vessel(s) reconstituted at or above the ankle with inline flow to at least one patent inframalleolar outflow vessel in each target vessel. If the peroneal artery is the treated artery, it should supply collaterals at the ankle that reconstitute an inframalleolar outflow vessel;
  11. Successful treatment of inflow stenosis (DS>50%), from the iliac to the target lesion. Stenosis can be treated during the same procedure using standard angioplasty, DCB, DES, and/or stenting but use of atherectomy is excluded. The inflow lesion(s) must be treated first, prior to consideration of treatment of the target lesion. Subject can be enrolled if the inflow lesion(s) are treated and results in \<30% residual stenosis and no evidence of embolization or significant complications.

Exclusion criteria

Exclusion Criteria:

  1. Rutherford Clinical Category 1, 2, or 6
  2. Evidence of aneurysm or acute thrombus in the target vessel.
  3. Subjects with previous bypass surgery in lower target extremity.
  4. Planned major amputation (above the ankle) of either limb.
  5. Subject has significant stenosis or occlusion of inflow tract not successfully treated (>30% residual stenosis and/or significant complication of the procedure).
  6. History of any open surgical procedure within the past 30 days.
  7. Planned endovascular procedure within 14 days prior to the BTK procedure, except to treat the inflow vessels on the day of the procedure, or a planned endovascular or open surgical procedure within the next 30 days after the BTK procedure on either limb.
  8. Planned intervention of occluded or stenotic pedal arteries at the time of the index procedure.
  9. Subject has an allergy to contrast medium that cannot be pretreated.
  10. Episode of acute limb ischemia within past 30 days.
  11. Subject has systemic infection with positive blood cultures/ bacteremia within one week.
  12. Subject has a hypercoagulable disorder
  13. Subject in whom antiplatelet, anticoagulant, or thrombolytic therapy is .
  14. Myocardial infarction within 30 days prior to enrollment.
  15. History of stroke or within 90 days prior to enrollment.
  16. Subject has acute or chronic renal disease (e.g., as measured by a serum creatinine of >2.5 mg/dL or >220 umol/L).
  17. Subject is pregnant or breastfeeding.
  18. Subject is participating in another research study of a device, medication, which could, in the opinion of the investigator, affect the results of this study.
  19. Subject has other medical, social or psychological problems that in the opinion of the investigator would preclude them from receiving this treatment and the procedures and or participating in evaluations pre- and post-treatment.
  20. Thrombolysis of the target vessel within 72 hours prior to the index procedure, where complete resolution of the thrombus was not achieved.
  21. Known allergies to both antiplatelet agents, aspirin, or heparin.
  22. History of neutropenia, coagulopathy, or thrombocytopenia that was unexplained or is considered to be at risk for reoccurrence.
  23. count less than 80,000/μL.
  24. Subject requires general anesthesia for the procedure.
  25. Subject requires dialysis.
  26. Subject has heel gangrene and anything worse than WIfI 2.

Angiographic Exclusion Criteria:

  1. De-novo, or non-stented re-stenotic lesions or Chronic Total Occlusions (CTO) > 12 cm in length.
  2. Acute Total Occlusions; evidence of acute thrombus formation by angiography.
  3. In-stent restenotic lesions.
  4. Inability to cross the lesion with a guidewire.
  5. Atherectomy for inflow treatment or planned use in below the knee vessel(s)
  6. Intended use of adjunctive primary treatment modalities of target lesion(s) (atherectomy, laser, cutting balloons, DCBs, stents).
  7. If two critical lesions are in one vessel but only one lesion qualifies, and the other does not, the subject should not be included in the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Other
    Single Arm, treated with Serranator

    Subjects treated with Serrantor

    Device: Serranator

Interventions

  • DeviceSerranator

    The Serranator® PTA Serration Balloon Catheter is an over-the-wire (OTW) balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.

07

What researchers measure

Primary outcomes

  1. Incidence of MALE and POD (Safety)

    Composite of Major Adverse Limb Events (MALE) and Peri-procedural Death (POD), assessed at 30 days post procedure. MALE plus POD is defined as a composite of all cause death, thrombolysis/thrombectomy at the target lesion, open surgical revision or bypass, and major (above ankle) target limb amputation at 30 days post procedure. Safety will be evaluated on a per subject basis.

    Time frame: 30 days post procedure

Secondary outcomes

  1. Rate of Device Success (Procedural Efficacy)

    Procedural efficacy will be assessed by the rate of device success defined as the achievement of successful insertion, balloon inflation and deflation, and removal of the study device(s) with a final diameter stenosis of \<50% by visual assessment at the intended target site using only the Serranator device. Device success will be evaluated on a per lesion basis.

    Time frame: Immediately Post Serranator treatment

08

Study locations

6 sites
  • Medical University of Graz
    Graz, A-8036, Austria
  • Klinikum Hochsauerland GmbH
    Arnsberg, 59759, Germany
  • Krankenhaus Buchholz
    Buchholz, 21244, Germany
  • Imland Klinik Rendsburg
    Rendsburg, 24768, Germany
  • Auckland City Hospital
    Auckland, Grafton 1023, New Zealand
  • Polsko-Amerykańskie Kliniki Serca PAKS
    Chrzanów, 32-050, Poland
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Apr 2020, 3 months.

Of 72 interventional studies with no phase under Chronic Limb-Threatening Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 85. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2018
First posted
Oct 3, 2018
StartActual
Dec 17, 2019
Primary completionActual
Apr 11, 2020
CompletionActual
Oct 23, 2020
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03693963
Lead sponsor
Cagent Vascular LLC
Responsible party
Sponsor
First posted
Oct 3, 2018
Start date
Dec 17, 2019
Primary completion
Apr 11, 2020
Completion
Oct 23, 2020
Last update
Jan 28, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion